| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2017-08-29 |
Alimera Sciences (USA - GA) Horus Pharma (France) |
Iluvien® (fluocinolone acetonide intravitreal implant) |
diabetic macular edema |
distribution |
Ophtalmological diseases |
Distribution agreement |
| 2017-08-29 |
Merck KGaA (Germany) Angiex (USA - MA) |
antibody drug conjugate therapy for cancer against the vascular target TM4SF1 |
|
development |
Cancer - Oncology |
Research agreement |
| 2017-08-29 |
Jazz Pharmaceuticals (Ireland) Immunogen (USA - MA) |
IMGN779, IMGN632 and an additional program to be designated |
hematological cancers |
development - commercialisation |
Cancer - Oncology |
Development agreement |
| 2017-08-29 |
Seattle Genetics (USA - WA) Genmab (Denmark) |
tisotumab vedotin (HuMax-TF-ADC) |
solid tumors |
licensing - development |
Cancer - Oncology |
Exercise of an option agreement |
| 2017-08-28 |
Aveo Oncology (USA - MA) Eusa Pharma (UK) |
tivozanib (N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N´-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate) |
advanced renal cell carcinoma |
licensing |
Cancer - Oncology |
Licensing agreement |
| 2017-08-28 |
BMS (USA - NY) Daiichi Sankyo (Japan) |
nivolumab and DS-8201 |
HER2-expressing metastatic breast cancer, HER2-expressing metastatic urothelial cancer |
clinical research |
Cancer - Oncology |
Clinical research agreement |
| 2017-08-25 |
Philogen (Italy) Servier (France) |
new small molecule-based therapeutics using ESAC platform and DNA-Encoded Chemistry technology |
|
research - R&D |
Technology - Services |
Research agreement |
| 2017-08-24 |
Novartis (Switzerland) |
Chief Digital Officer |
|
nomination |
|
Nomination |
| 2017-08-24 |
Lonza (Switzerland) |
new capacities for drug product process development in Basel |
|
construction of new premises |
Technology - Services |
Construction of new premises |
| 2017-08-24 |
Bioverativ (USA - MA) Invicro (USA - MA) |
imaging technologies, including ultrasound and radiolabeled imaging, to improve the diagnosis and management of joint disease in people with hemophilia |
joint disease in people with hemophilia |
collaboration |
Rare diseases - Genetic diseases - Hematological diseases - Diagnosis |
Collaboration agreement |
| 2017-08-22 |
Crispr Therapeutics (Switzerland - UK) Massachusetts General Hospital Cancer Center (USA - MA) |
T cell therapies in development, ultimately addressing unmet needs in both hematologic and solid tumors |
hematological cancers, solid tumors |
research - licensing |
Cancer - Oncology |
Research agreement |
| 2017-08-22 |
Atara Biotherapeutics (USA - CA) |
chief medical officer |
|
nomination |
Cancer - Oncology |
Nomination |
| 2017-08-21 |
Samsung Bioepis (Republic of Korea) Takeda Pharmaceutical (Japan) |
novel biologic therapies including TAK-671 |
acute pancreatitis, undisclosed diseases |
development - collaboration |
Inflammatory diseases |
Development agreement |
| 2017-08-21 |
AstraZeneca (UK) Ethris (Germany) |
stabilised non-immunogenic modified RNA therapies |
asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis |
research - R&D |
Rare diseases - Pulmonary diseases - Respiratory diseases - Allergic diseases |
Research agreement |
| 2017-08-21 |
Bavarian Nordic (Denmark) Janssen Pharmaceuticals, a J&J company (USA - NJ) |
- MVA-BN® technology for two programs targeting vaccines against hepatitis B virus (HBV) and the human immunodeficiency virus (HIV-1)
|
HIV-1 infection, hepatitis B |
development - licensing - commercialisation |
Infectious diseases |
Licensing agreement |
| 2017-08-18 |
Medivir (Sweden) Ascletis (China) |
MIV-802 |
hepatitis C |
licensing |
Infectious diseases |
Licensing agreement |
| 2017-08-16 |
Abcam (UK) TTP Labtech (UK) |
reagent kits for the quantification of secreted proteins |
|
collaboration - research - R&D |
Technology - Services |
Collaboration agreement |
| 2017-08-16 |
National Cancer Institute (NCI) (USA) Sillajen (Republic of Korea) |
pexastimogene devacirepvec (Pexa-Vec) anti-PDL1 and anti-CTLA4 antibodies |
advanced colorectal cancer |
development |
Cancer - Oncology |
Development agreement |
| 2017-08-14 |
Aduro Biotech (USA - CA) HitGen (China) |
|
|
research |
undisclosed |
Research agreement |
| 2017-08-11 |
Oxford Biomedica (UK) Cell and Gene Therapy Catapult (UK) Stratophase (UK) Synthace (UK) |
gene and cell therapy manufacturing |
|
collaboration |
Technology - Services |
Collaboration agreement |
